Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 Feb;31(2):259–263. doi: 10.1128/aac.31.2.259

Comparative evaluation of A-56619, A-56620, and nafcillin in the treatment of experimental Staphylococcus aureus osteomyelitis.

J T Mader, L T Morrison, K R Adams
PMCID: PMC174702  PMID: 3566251

Abstract

A rabbit model for Staphylococcus aureus osteomyelitis was used to compare the results of treatment with A-56619 and A-56620, two new aryl-fluoroquinolones, and nafcillin. A-56619 (15 mg/kg) and A-56620 (20 mg/kg), both used for 28 days of treatment, were injected subcutaneously every 12 h, and nafcillin (40 mg/kg) was injected every 6 h. After treatment, S. aureus was found on bone marrow cultures from 19 of 20 control rabbits, 6 of 20 treated with A-56619, 14 of 20 treated with A-56620, and 8 of 20 treated with nafcillin. Drug concentrations in serum and uninfected and infected bone were measured 1 h after A-56619 and A-56620 injection and 30 min after nafcillin injection in a group of rabbits that had been infected for 3 to 4 weeks. The concentrations in infected bone were similar for all three drugs and were significantly higher than in uninfected bone. The results of this study showed that A-56619 had a high rate of eradication of S. aureus from infected bone and compared favorably to nafcillin.

Full text

PDF
259

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Eliopoulos G. M., Moellering A. E., Reiszner E., Moellering R. C., Jr In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620. Antimicrob Agents Chemother. 1985 Oct;28(4):514–520. doi: 10.1128/aac.28.4.514. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Mader J. T., Brown G. L., Guckian J. C., Wells C. H., Reinarz J. A. A mechanism for the amelioration by hyperbaric oxygen of experimental staphylococcal osteomyelitis in rabbits. J Infect Dis. 1980 Dec;142(6):915–922. doi: 10.1093/infdis/142.6.915. [DOI] [PubMed] [Google Scholar]
  3. Mader J. T., Guckian J. C., Glass D. L., Reinarz J. A. Therapy with hyperbaric oxygen for experimental osteomyelitis due to Staphylococcus aureus in rabbits. J Infect Dis. 1978 Sep;138(3):312–318. doi: 10.1093/infdis/138.3.312. [DOI] [PubMed] [Google Scholar]
  4. Mader J. T., Wilson K. J. Comparative evaluation of cefamandole and cephalothin in the treatment of experimental Staphylococcus aureus osteomyelitis in rabbits. J Bone Joint Surg Am. 1983 Apr;65(4):507–513. [PubMed] [Google Scholar]
  5. Norden C. W. Experimental osteomyelitis. I. A description of the model. J Infect Dis. 1970 Nov;122(5):410–418. doi: 10.1093/infdis/122.5.410. [DOI] [PubMed] [Google Scholar]
  6. Norden C. W. Experimental osteomyelitis. II. Therapeutic trials and measurement of antibiotic levels in bone. J Infect Dis. 1971 Dec;124(6):565–571. doi: 10.1093/infdis/124.6.565. [DOI] [PubMed] [Google Scholar]
  7. Norden C. W. Experimental osteomyelitis. IV. Therapeutic trials with rifampin alone and in combination with gentamicin, sisomicin, and cephalothin. J Infect Dis. 1975 Nov;132(5):493–499. doi: 10.1093/infdis/132.5.493. [DOI] [PubMed] [Google Scholar]
  8. Norden C. W., Shaffer M. Treatment of experimental chronic osteomyelitis due to staphylococcus aureus with vancomycin and rifampin. J Infect Dis. 1983 Feb;147(2):352–357. doi: 10.1093/infdis/147.2.352. [DOI] [PubMed] [Google Scholar]
  9. Norden C. W., Shinners E. Ciprofloxacin as therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa. J Infect Dis. 1985 Feb;151(2):291–294. doi: 10.1093/infdis/151.2.291. [DOI] [PubMed] [Google Scholar]
  10. Norden C. W., Shinners E., Niederriter K. Clindamycin treatment of experimental chronic osteomyelitis due to Staphylococcus aureus. J Infect Dis. 1986 May;153(5):956–959. doi: 10.1093/infdis/153.5.956. [DOI] [PubMed] [Google Scholar]
  11. Reynolds A. V., Hamilton-Miller J. M., Brumfitt W. Diminished effect of gentamicin under anaerobic or hypercapnic conditions. Lancet. 1976 Feb 28;1(7957):447–449. doi: 10.1016/s0140-6736(76)91474-4. [DOI] [PubMed] [Google Scholar]
  12. Smith B. R., LeFrock J. L., Donato J. B., Joseph W. S., Weber S. J. In vitro activity of A-56619 and A56620, two new aryl-fluoroquinolone antimicrobial agents. Antimicrob Agents Chemother. 1986 Feb;29(2):355–358. doi: 10.1128/aac.29.2.355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Stamm J. M., Hanson C. W., Chu D. T., Bailer R., Vojtko C., Fernandes P. B. In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones. Antimicrob Agents Chemother. 1986 Feb;29(2):193–200. doi: 10.1128/aac.29.2.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Verklin R. M., Jr, Mandell G. L. Alteration of effectiveness of antibiotics by anaerobiosis. J Lab Clin Med. 1977 Jan;89(1):65–71. [PubMed] [Google Scholar]
  15. Waldvogel F. A., Medoff G., Swartz M. N. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. N Engl J Med. 1970 Jan 22;282(4):198–206. doi: 10.1056/NEJM197001222820406. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES